Qutavina

RSS
Withdrawn

This medicine's authorisation has been withdrawn

teriparatide
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 24 November 2020, the European Commission withdrew the marketing authorisation for Qutavina (teriparatide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, EuroGenerics Holdings B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Qutavina was granted marketing authorisation in the EU on 27 August 2020 for the treatment of osteoporosis. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since 2020. Qutavina was a duplicate application to Livogiva, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Livogiva.

The European Public Assessment Report (EPAR) for Qutavina is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (1.35 MB - PDF)

View

español (ES) (725.86 KB - PDF)

View

čeština (CS) (798.67 KB - PDF)

View

dansk (DA) (724.75 KB - PDF)

View

Deutsch (DE) (730.66 KB - PDF)

View

eesti keel (ET) (709.32 KB - PDF)

View

ελληνικά (EL) (819.31 KB - PDF)

View

français (FR) (728.34 KB - PDF)

View

hrvatski (HR) (747.09 KB - PDF)

View

italiano (IT) (724.03 KB - PDF)

View

latviešu valoda (LV) (815.37 KB - PDF)

View

lietuvių kalba (LT) (749.58 KB - PDF)

View

magyar (HU) (793.63 KB - PDF)

View

Malti (MT) (798.96 KB - PDF)

View

Nederlands (NL) (698.91 KB - PDF)

View

polski (PL) (797.33 KB - PDF)

View

português (PT) (725.9 KB - PDF)

View

română (RO) (746.69 KB - PDF)

View

slovenčina (SK) (796.21 KB - PDF)

View

slovenščina (SL) (792.9 KB - PDF)

View

Suomi (FI) (722.29 KB - PDF)

View

svenska (SV) (724.89 KB - PDF)

View

Product information

български (BG) (2.99 MB - PDF)

View

español (ES) (2.54 MB - PDF)

View

čeština (CS) (3.18 MB - PDF)

View

dansk (DA) (2.6 MB - PDF)

View

Deutsch (DE) (2.65 MB - PDF)

View

eesti keel (ET) (2.6 MB - PDF)

View

ελληνικά (EL) (3.89 MB - PDF)

View

français (FR) (2.58 MB - PDF)

View

hrvatski (HR) (2.64 MB - PDF)

View

íslenska (IS) (2.55 MB - PDF)

View

italiano (IT) (2.63 MB - PDF)

View

latviešu valoda (LV) (3.16 MB - PDF)

View

lietuvių kalba (LT) (2.73 MB - PDF)

View

magyar (HU) (3.14 MB - PDF)

View

Malti (MT) (3.27 MB - PDF)

View

Nederlands (NL) (2.54 MB - PDF)

View

norsk (NO) (2.55 MB - PDF)

View

polski (PL) (2.59 MB - PDF)

View

português (PT) (1.97 MB - PDF)

View

română (RO) (2.07 MB - PDF)

View

slovenčina (SK) (2.55 MB - PDF)

View

slovenščina (SL) (2.54 MB - PDF)

View

Suomi (FI) (2.56 MB - PDF)

View

svenska (SV) (1.98 MB - PDF)

View
24/11/2020
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (654.59 KB - PDF)

View

español (ES) (616.53 KB - PDF)

View

čeština (CS) (649.54 KB - PDF)

View

dansk (DA) (618.63 KB - PDF)

View

Deutsch (DE) (617.71 KB - PDF)

View

eesti keel (ET) (615.29 KB - PDF)

View

ελληνικά (EL) (652.38 KB - PDF)

View

français (FR) (616.04 KB - PDF)

View

hrvatski (HR) (692.56 KB - PDF)

View

íslenska (IS) (617.45 KB - PDF)

View

italiano (IT) (615.9 KB - PDF)

View

latviešu valoda (LV) (648.55 KB - PDF)

View

lietuvių kalba (LT) (633.92 KB - PDF)

View

magyar (HU) (648.08 KB - PDF)

View

Malti (MT) (649.09 KB - PDF)

View

Nederlands (NL) (616.41 KB - PDF)

View

norsk (NO) (617.27 KB - PDF)

View

polski (PL) (653.33 KB - PDF)

View

português (PT) (617.49 KB - PDF)

View

română (RO) (630.89 KB - PDF)

View

slovenčina (SK) (667.48 KB - PDF)

View

slovenščina (SL) (648.68 KB - PDF)

View

Suomi (FI) (615.5 KB - PDF)

View

svenska (SV) (616.39 KB - PDF)

View

Product details

Name of medicine
Qutavina
Active substance
teriparatide
International non-proprietary name (INN) or common name
teriparatide
Therapeutic area (MeSH)
Osteoporosis
Anatomical therapeutic chemical (ATC) code
H05AA02

Pharmacotherapeutic group

Calcium homeostasis

Therapeutic indication

Qutavina is indicated in adults.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Authorisation details

EMA product number
EMEA/H/C/005388

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.

Marketing authorisation holder
EuroGenerics Holdings B.V.

Locatellikade 1
1076 AZ Amsterdam
The Netherlands

Marketing authorisation issued
27/08/2020
Withdrawal of marketing authorisation
24/11/2020

Assessment history

This page was last updated on

Share this page